Multi-center survey regarding the management of anticoagulation and antiplatelet therapy for endoscopic procedures in Japan

被引：36

作者：

Fujishiro, Mitsuhiro ^{[1
]}

Oda, Ichiro ^{[2
]}

Yamamoto, Yorimasa ^{[3
]}

Akiyama, Junichi ^{[4
]}

Ishii, Naoki ^{[5
]}

Kakushima, Naomi ^{[10
]}

Fujiwara, Junko ^{[6
]}

Morishita, Shinji ^{[7
]}

Kawachi, Hiroshi ^{[8
]}

Taniguchi, Hirokazu ^{[9
]}

Gotoda, Takuji ^{[2
]}

机构：

[1] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo, Japan

[2] Natl Canc Ctr, Endoscopy Div, Tokyo, Japan

[3] Japanese Fdn Canc Res, Canc Inst Hosp, Gastroenterol Ctr, Tokyo, Japan

[4] Internal Med Ctr Japan, Dept Gastroenterol, Tokyo, Japan

[5] St Lukes Int Hosp, Dept Gastroenterol, Tokyo, Japan

[6] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Gastroenterol, Tokyo, Japan

[7] Tokyo KoseiNenkin Hosp, Dept Gastroenterol, Tokyo, Japan

[8] Tokyo Med & Dent Univ, Dept Pathol, Tokyo, Japan

[9] Natl Canc Ctr, Dept Pathol, Tokyo, Japan

[10] Saitama Med Univ Int, Med Ctr, Gastroenterol Ctr, Saitama, Japan

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2009年 / 24卷 / 02期

关键词：

aspirin; endoscopic biopsy; endoscopic mucosal resection; endoscopic submucosal dissection; warfarin; GASTROINTESTINAL ENDOSCOPY; AGENTS; GUIDELINE; RISK;

D O I：

10.1111/j.1440-1746.2008.05604.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

A guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures has been established from Japan Gastroenterological Endoscopy Society in 2005. However, it is unknown whether consensus on the management of these conditions is obtained among endoscopists in daily practice owing to the guideline. To study the current practice on the management, survey questionnaires were sent to 13 representative endoscopists of 13 middle or high-volume hospitals in the Tokyo area. Responses were obtained from all 13 endoscopists. The results showed that only five (38%) and six (46%) hospitals had their own standard protocols regarding the management for endoscopic biopsy and endoscopic mucosal resection (EMR), respectively. There was a wide variation among endoscopists in terms of discontinuation of each agent. When the patients had a major risk of thromboembolism due to discontinuation of anticoagulants and antiplatelet agents, seven (54%) and five (38%) endoscopists, respectively, never took a biopsy. Similar numbers of endoscopists never carried out EMR. During discontinuation of anticoagulants or antiplatelet agents for biopsy and EMR, three (23%) and three (23%) endoscopists, respectively, experienced patients with thromboembolic events. There is still a wide variation and confusion among endoscopists after establishment of our national guideline. A robust national guideline with clearer description based on the scientific evidence is needed.

引用

页码：214 / 218

页数：5

共 20 条

[1]

[Anonymous], 2005, GASTROENTEROL ENDOS

[2]

Management of anticoagulants and antiplatelet agents in elective endoscopy: Weighing the risks and benefits [J].